Multi-platform molecular profiling increases the median overall survival of those who receive treatment with clinical benefit by 422 days from time of profiling.
Study demonstrates Next-Generation Sequencing can determine microsatellite instability status among cancer types, identifies subset of patients who may benefit from immunotherapy.
Caris’s biomarker driven therapy demonstrates clinical benefit for nearly 30% of patients with difficult-to-treat metastatic gastric and oesophageal cancer.
Pilot study shows applicability of Caris Molecular Intelligence to improve patient outcomes in clinical practice.
Caris Molecular Intelligence has the highest clinical utility and is improving patient outcomes in clinical practice.
Comparison of four commercially available tumour profiling services highlights superiority of Caris Molecular Intelligence.
Patients with rare and heavily pretreated solid tumours show significant clinical benefit after Caris Molecular Intelligence-guided treatment.
Background Adrenal cortex adenocarcinoma is a rare cancer affecting the cortex of the adrenal glands. It has an incidence of 1-2 cases per million inhabitants per year.1 The disease incidence is greatest in the first decade of life and between the ages of 40 to 50 years.2 Treatment can be challenging for patients who present...
Background In 2013 in Australia, the age-standardised incidence rate for cervical cancer was 6.8 cases per 100,000 females, and 813 people were newly diagnosed with cervical cancer.1 The rate and mortality of cervical cancer has halved since the National Cervical Screening Program was implemented in 1991.1 Although these improvements have been made, the prognosis of...
NH: Hello and thank you for tuning into the program. I’m your host Neil Howard here on Health Professional Radio. Our guest today is Chief Scientific Officer at Caris Life Sciences, joining us here today to talk about his company’s involvement with several studies where cancer is being treated based on its molecular profile rather...